1.Bartzokis G. Acetylcholinesterase inhibitors may improve myelin integrity. Biol Psychiat 2007; 62: 294—301.2.Bullock R., Lane R. Executive dyscontrol in dementia, with emphasis on subcortical pathology and the role of butyrylcholinesterase. Curr Alzheimer Res 2007; 4: 277—293.3.Cummings J., Emre M., Aarsland D. et al. Effects of rivastigmine in Alzheimer’s disease patients with and without hallucinations. J Alz Dis 2010; 20: 301—311.4.Das N.U. Acetylcholinesterase and butyrylcholinesterase as possible markers of low-grade systemic inflammation. Med SciMonit 2007; 13: RA214—RA221.5.Farlow M.R., Cummings J.L. Effective pharmacologic management of Alzheimer’s disease. Am J Med 2007; 120: 388—397.6.Feldman H.H., Ferris S., Winblad B. et al. Effect of rivastigmine on delay to diagnosis of Alzheimer’s diseasefrom mild cognitive impairment: the InDDEx study. Lancet Neurol 2007; 6: 501—512.7.Ferris S., Lane R., Sfikas N. et al. Effects of gender on response to treatment with rivastigmine in mild cognitive impairment: a post hoc statistical modeling approach. Gender Med 2009; 6: 345—355.8.Ferris S., Nordberg A., Soininen H. et al. Progression from mild cognitive impairment to Alzheimer’s disease: effects of sex, butyrylcholinesterase genotype, and rivastigmine treatment. Pharmacogenet.Genomics 2009; 19: 635—636.9.Hsu J.L., Leemans A., Bai C.H. et al. Gender differences and age-related white matter changes of the human brain: a diffusion tensor imaging study. NeuroImage 2008; 39: 566—577.10.Lane R.M., Potkin S.G., Enz A. Targeting acetylcholinesterase and butyrylcholinesterase in dementia. Internat. J Neuropsychopharmacol 2006; 9: 101—124.11.Nizri E., Irony-Tur-Sinai M., Faranesh N. et al. Suppression of neuroinflammation and immunomodulation by the acetylcholinesterase inhibitor rivastigmine. J Neuroimmunol 2008; 203: 12—22.12.Perry E., Ziabreva I., Perry R. et al. Absence of cholinergic deficits in «pure» vascular dementia. Neurology 2005; 64: 132—133.13.Rakhmonova H.N., Rakhmonov Z.M. Innervation Relationships of the Gallbladder Nerve Apparatus with Spinal and Rheumatic Nerve Ganglia (Literature Review).Eurasian Medical Research Periodical,18, 105-108.14.Rakhmonova Kh.N. Morphological bases of innervational connections of the nervous apparatus of the gallbladder Journal of Problems in Biology and Medicine, PBIM 2022 No6 (140), 387-392.15.Royall D.R. The emperor has no clothes: Dementia treatment on the Eve of the Aging Era. J Am Geriat Soc 2005; 53: 1: 163—164.16.Shanks M., Kivipelto M., Bullock R., Lane R. Cholinesterase inhibition: is there evidence for disease-modifyingeffects? Curr Med Res Opin 2009; 25: 2439—2446.17.Tavassoli N., Sommet A., Lapeyre-Mestre M. et al. Drug interactions with cholinesterase inhibitors: An analysis of the French pharmacovigilance database and a comparison of two national drug formularies (Vidal, British National Formulary). Drug Safety 2007; 30: 1063—1071.18.Venneri A., Lane R. Effects of cholinesterase inhibition on brain white matter volume in Alzheimer’s disease. NeuroReport 2009; 20: 285—288.19.Wesnes K.A., McKeith I., Edgar C. et al. Benefitsof rivastigmine on attention in dementia associated with Parkinson disease. Neurology 2005; 65: 1654—1656.20.Winblad B., Grossberg G., Frolich L. et al. IDEAL: A 6-month, doubleblind, placebo-controlled study of the first skin patch for Alzheimer disease. Neurology 2007; 69: Suppl 1: S14—S22.21.Winblad B., Machado J.C. Use of rivastigmine transdermal patch in the treatment of Alzheimer’s disease. Expert Opin Drug Deliv 2008; 5: 1—10.22.Кондратьева Е.А., Боровикова В.Н., Кондратьев С.А. и др. Роль ривастигмина (экселона) в лечении последствий черепно-мозговой травмы. Журн неврол и психиат 2009; 109: 55—58.23.Локшина А.Б., Захаров В.В. Легкие и умеренные когнитивные расстройства при дисциркуляторной энцефалопатии. Неврол журн 2006; 11: прил. 1: 57—64.24.Яхно Н.Н. Когнитивные расстройства в неврологической клинике Неврол журн 2006; 11: прил. 1: 4—13.